Escudero-Pérez Beatriz, Muñoz-Fontela César
Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
German Center for Infection Research, Partner Site, 20359 Hamburg, Germany.
Vaccines (Basel). 2019 Feb 20;7(1):22. doi: 10.3390/vaccines7010022.
Filoviruses, such as Ebola and Marburg virus, encode viral proteins with the ability to counteract the type I interferon (IFN-I) response. These IFN-I antagonist proteins are crucial to ensure virus replication, prevent an antiviral state in infected and bystander cells, and impair the ability of antigen-presenting cells to initiate adaptive immune responses. However, in recent years, a number of studies have underscored the conflicting data between in vitro studies and in vivo data obtained in animal models and clinical studies during outbreaks. This review aims to summarize these data and to discuss the relative contributions of IFN-α and IFN-β to filovirus pathogenesis in animal models and humans. Finally, we evaluate the putative utilization of IFN-I in post-exposure therapy and its implications as a biomarker of vaccine efficacy.
丝状病毒,如埃博拉病毒和马尔堡病毒,编码具有抵消I型干扰素(IFN-I)反应能力的病毒蛋白。这些IFN-I拮抗剂蛋白对于确保病毒复制、防止受感染细胞和旁观者细胞进入抗病毒状态以及损害抗原呈递细胞启动适应性免疫反应的能力至关重要。然而,近年来,一些研究强调了体外研究与在动物模型以及疫情期间的临床研究中获得的体内数据之间相互矛盾。本综述旨在总结这些数据,并讨论IFN-α和IFN-β在动物模型和人类丝状病毒发病机制中的相对作用。最后,我们评估IFN-I在暴露后治疗中的潜在应用及其作为疫苗疗效生物标志物的意义。